| Literature DB >> 35312085 |
Wei You1, Yuhe Zhou2, Zhiming Wu1, Peina Meng1, Defeng Pan3, Delu Yin4, Song Yang5, Xiangqi Wu1, Fei Ye1.
Abstract
BACKGROUND: The study sought to investigate the clinical predictive value of quantitative flow ratio (QFR) for the long-term outcome in patients with heavily calcified lesions who underwent percutaneous coronary intervention (PCI) following rotational atherectomy (RA).Entities:
Keywords: calcified lesion; patients; percutaneous coronary intervention; quantitative flow ratio; rotational atherectomy
Mesh:
Year: 2022 PMID: 35312085 PMCID: PMC9045081 DOI: 10.1002/clc.23816
Source DB: PubMed Journal: Clin Cardiol ISSN: 0160-9289 Impact factor: 3.287
Figure 1The study flowchart. PCI, percutaneous coronary intervention; QFRv, vessel quantitative flow ratio; QFRi, quantitative flow ratio in a segment; RA, rotational atherectomy; TLF, target lesion failure; TL‐CD, target lesion‐cardiac death; TL‐MI, target lesion‐myocardial infarction; TLR, target lesion revascularization
Basic clinic, procedural, and QCA data of patients with heavily calcified lesions with and without TLF after RA
| Variable | TLF ( | Non‐TLF ( |
|
|---|---|---|---|
| Age, years | 71.5 ± 8.0 | 71.0 ± 7.6 | .690 |
| Male (%) | 33 (63.5%) | 119 (69.2%) | .439 |
| Family history of CAD (%) | 2 (3.8%) | 5 (2.9%) | .665 |
| CV risk factors | |||
| Hyperlipidemia (%) | 38 (73.1%) | 117 (68.0%) | .489 |
| Hypertension (%) | 36 (69.2%) | 132 (76.7%) | .273 |
| Diabetes (%) | 23 (44.2%) | 68 (39.5%) | .546 |
| Current smoker (%) | 21 (40.4%) | 70 (40.7%) | .968 |
| Renal insufficiency (%) | 5 (9.6%) | 9 (5.2%) | .323 |
| Hemodialysis (%) | 2 (3.8%) | 4 (2.3%) | .625 |
| Clinical diagnosis | .512 | ||
| SAP (%) | 11 (21.2%) | 29 (16.9%) | |
| UAP (%) | 27 (51.9%) | 105 (61.0%) | |
| NSTEMI (%) | 5 (9.6%) | 19 (11.0%) | |
| STEMI (%) | 9 (17.3%) | 19 (11.0%) | |
| Antiplatelet therapy | |||
| Aspirin (%) | 52 (100%) | 172 (100%) | – |
| Clopidogrel/Ticagrelor (%) | 52 (100%) | 172 (100%) | – |
| Clopidogrel (%) | 32 (61.5%) | 113 (65.7%) | .582 |
| Statin therapy (%) | .128 | ||
| Atorvastatin | 30 (57.7%) | 88 (51.2%) | |
| Rosuvastatin | 20 (38.5%) | 77 (44.8%) | |
| Simvastatin | 0 (0%) | 6 (3.5%) | |
| QCA data | |||
| Vessel disease number | .250 | ||
| Single vessel disease (%) | 9 (17.3%) | 43 (25.0%) | |
| Multiple vessel disease (%) | 43 (82.7%) | 129 (75.0%) | |
| Target vessels | .020 | ||
| LAD (%) | 34 (65.4%) | 143 (83.1%) | |
| RCA (%) | 14 (26.9%) | 21 (12.2%) | |
| LCX (%) | 4 (7.7%) | 8 (4.7%) | |
| Pre‐PCI distal RVD (mm) | 2.4 (2.1,2.6) | 2.3 (2.0,2.7) | .228 |
| Pre‐PCI proximal RVD (mm) | 2.8 (2.3,3.2) | 2.8 (2.4,3.2) | .465 |
| Pre‐PCI MLD (mm) | 0.6 (0.5,0.8) | 0.5 (0.6,0.7) | .055 |
| Pre‐PCI DS (%) | 74.7 (66.7,79.4) | 75.9 (70.0,80.8) | .250 |
| Lesion length (mm) | 56.2 (45.8,69.8) | 56.2 (43.3,70.0) | .734 |
| Procedure data | |||
| Initial burr size (mm) | 1.40 ± 0.20 | 1.42 ± 0.18 | .474 |
| Final burr size (mm) | 1.48 ± 0.22 | 1.50 ± 0.18 | .516 |
| Pre‐dilated balloon diameter (mm) | 2.63 ± 0.44 | 2.66 ± 0.38 | .549 |
| Pre‐dilated pressure (atm) | 19.65 ± 2.95 | 18.91 ± 2.63 | .084 |
| Post‐dilated balloon diameter (mm) | 3.47 ± 0.63 | 3.49 ± 0.58 | .827 |
| Post‐dilated pressure (atm) | 20.65 ± 1.91 | 19.95 ± 1.71 | .013 |
| Post‐PCI distal RVD (mm) | 2.6 (2.2,3.0) | 2.6 (2.3,3.0) | .787 |
| Post‐PCI proximal RVD (mm) | 3.1 (2.7,3.7) | 3.1 (2.6,3.5) | .218 |
| Post‐PCI MLD (mm) | 1.6 (1.4,2.0) | 1.9 (1.7,2.2) | .001 |
| Post‐PCI DS (%) | 32.1 (26.9,39.5) | 26.4 (22.6,30.8) | ≤.001 |
| Total stent length (mm) | 63.5 (50.5,76.5) | 61.5 (47.8,76.0) | .461 |
| Average stent diameter (mm) | 3.0 (2.8,3.3) | 2.9 (2.7,3.1) | .259 |
| Stent number | 2.0 (2.0,3.0) | 2.0 (2.0,3.0) | .326 |
| QFRv post PCI | 0.848 ± 0.144 | 0.904 ± 0.100 | .079 |
| QFRi post PCI | 0.915 ± 0.066 | 0.978 ± 0.034 | ≤.001 |
| Burr to vessel ratio | 0.63 (0.52,0.70) | 0.65 (0.56,0.74) | .156 |
| Imaging use (%) | 30 (57.7%) | 92 (53.5%) | .636 |
| CB use (%) | 8 (15.4%) | 24 (14.0%) | .822 |
| FV post PCI (m/s) | 0.21 (0.16,0.23) | 0.18 (0.14, 0.23) | .101 |
Note: Data were expressed as n (%), mean ± SD, and median (quartile 1, quartile 3).
Abbreviations: CB, cutting balloon; CV, cardiovascular; DS, diameter stenosis; FV, flow velocity; LAD, left anterior descending coronary artery; LCX, left circumflex coronary; MLD, minimal luminal diameter; NSTEMI, non‐ST‐segment elevation myocardial infarction; PCI, percutaneous coronary intervention; QCA, quantitative coronary angiography; QFRi, quantitative flow ratio in a segment; QFRv, vessel quantitative flow ratio; RCA, right coronary artery; RVD, reference vessel diameter; SAP, stable angina pectoris; SD, standard deviation; STEMI, ST‐segment elevation myocardial infarction; TLF, target lesion failure; UAP, unstable angina pectoris.
Predictors of TLF were analyzed by the Cox regression method
| Variables | Univariate analysis |
| Multivariate analyses |
|
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Male (%) | 1.246 (0.708–2.191) | .445 | ||
| Age (years) | 1.007 (0.972–1.044) | .696 | ||
| Hypertension (%) | 0.738 (0.409–1.329) | .311 | ||
| Hyperlipidemia (%) | 1.236 (0.670–2.282) | .498 | ||
| Diabetes (%) | 1.184 (0.685–2.046) | .546 | ||
| Smoking (%) | 0.984 (0.566–1.713) | .956 | ||
| Single‐vessel lesion (%) | 0.643 (0.313–1.318) | .228 | ||
| Multiple‐vessel lesion (%) | 1.556 (0.758–3.192) | .228 | ||
| Target‐lesion length (mm) | 1.001 (0.989–1.013) | .915 | ||
| pre‐PCI DS (%) | 0.989 (0.961–1.018) | .464 | ||
| Initial burr size (mm) | 0.539 (0.112–2.600) | .441 | ||
| Final burr size (mm) | 0.548 (0.120–2.497) | .437 | ||
| Pre‐dilated balloon diameter (mm) | 0.779 (0.384–1.581) | .490 | ||
| Pre‐dilated pressure (atm) | 1.089 (0.992–1.196) | .073 | ||
| Post‐dilated balloon diameter (mm) | 0.922 (0.575–1.478) | .735 | ||
| Post‐dilated pressure (atm) | 1.188 (1.038–1.360) | .012 | 1.081 (0.949–1.231) | .241 |
| Target‐vessel stent length (mm) | 1.003 (0.991–1.015) | .608 | ||
| MLD post PCI (mm) | 0.239 (0.110–0.518) | ≤.001 | 1.330 (0.572–3.094) | .508 |
| DS post PCI (%) | 1.090 (1.060–1.121) | ≤.001 | 1.067 (1.036–1.100) | ≤.001 |
| QFRv post PCI | 0.048 (0.008–0.290) | .001 | 2.382 (0.145–39.073) | .543 |
| QFRi post PCI | 1.2E−07 (3.0E−09–4.8E−06) | ≤.001 | 1.7E−8 (5.3E−11–5.6E−6) | ≤.001 |
| B to V ratio | 0.152 (0.020–1.138) | .067 | ||
| Imaging use (%) | 1.156 (0.667–2.004) | .605 | ||
| CB use (%) | 1.068 (0.503–2.269) | .864 | ||
| LAD (%) | 0.439 (0.248–0.778) | .005 | 0.383 (0.210–0.697) | .002 |
| FV post PCI (m/s) | 15.642 (0.563–434.677) | .105 |
Abbreviations: B to V, burr to vessel; CB, cutting balloon; CI, confidential interval; DS, diameter stenosis; FV, flow velocity; HR, hazard ratio; LAD, left anterior descending coronary artery; MLD, minimal luminal diameter; PCI, percutaneous coronary intervention; QFRi, quantitative flow ratio in a segment; QFRv, vessel quantitative flow ratio; TLF, target lesion failure.
Figure 2ROC curve analysis of QFRi post‐PCI to predict TLF in patients with heavily calcified lesions after RA at the 3‐year follow‐up. The cutoff value of QFRi post‐PCI for predicting TLF was 0.94 (sensitivity: 0.895, specificity: 0.692). PCI, percutaneous coronary intervention; QFRi, quantitative flow ratio in a segment; RA, rota atherectomy; ROC, receiver operating characteristic curve; TLF, target lesion failure
The clinical outcome between the high‐ and low‐QFR groups after about 3 years post‐PCI
| QFR > 0.94 ( | QFR ≤ 0.94 ( |
| |
|---|---|---|---|
| TLF (%) | 16 (9.4%) | 36 (66.7%) | ≤.001 |
| TL‐CD (%) | 6 (3.5%) | 6 (11.1%) | .042 |
| TL‐MI (%) | 5 (2.9%) | 11 (20.4%) | ≤.001 |
| TLR (%) | 10 (5.9%) | 30 (55.6%) | ≤.001 |
Note: Data were expressed as n (%).
Abbreviations: PCI, percutaneous coronary intervention; QFRi, quantitative flow ratio; TL‐CD, target lesion‐cardiac death; TL‐MI, target lesion‐myocardial infarction; TLF, target lesion failure; TLR, target lesion revascularization.
Figure 3TLF and its compositions were analyzed by the Kaplan–Meier curves between the high‐ and low‐QFRi groups at the 3‐year follow‐up. (A) TLF; (B) TL‐CD; (C) TL‐MI; (D) TLR. TLF, target lesion failure; TL‐CD, target lesion‐cardiac death; TL‐MI, target lesion‐myocardial infarction; TLR, target lesion revascularization